News Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-03-14 pm EDT			5-day change	1st Jan Change
162.81 ^USD	-0.11%		-2.33%	+12.58%

Mar. 13	Trump's tariffs and threatened trade actions	RE
Mar. 12	Lilly, J&J boosted spending on executive security after UnitedHealth shooting	RE

Trump's tariffs and threatened trade actions	Mar. 13	RE
Lilly, J&J boosted spending on executive security after UnitedHealth shooting	Mar. 12	RE
Johnson & Johnson : 2025 Proxy Statement and additional solicitation materials (Johnson Johnson 2025 Proxy)	Mar. 12	PU
Johnson & Johnson : Meeting agenda (2025 Meeting agenda)	Mar. 12	PU
Lilly, J&J boosted spending on executive security after UnitedHealth shooting	Mar. 12	RE
J&J: MONARCH QUEST tool approved in the USA	Mar. 12	CF
Johnson & Johnson's MedTech Gets US FDA Approval for Monarch Quest	Mar. 12	MT
J&J Medtech gets regulatory clearance for its latest robotic-assisted bronchoscopy technology	Mar. 12	RE
J&J Says CEO Joaquin Duato's 2024 Total Compensation Was $24.3 Million Versus $28.4 Million In 2023 - SEC Filing	Mar. 12	RE
Mercy Investment Services Submits Shareholder Proposal with Johnson & Johnson	Mar. 12	CI
Johnson & Johnson Solicits Proxies from Shareholders	Mar. 12	CI
Johnson & Johnson Solicits Proxies from Shareholders	Mar. 12	CI
John Chevedden Submits Shareholder Proposal with Johnson & Johnson	Mar. 12	CI
Barclays Keeps Genmab at Overweight After J&J Drops Licensing Plan for Blood Cancer Drug	Mar. 12	MT
Investigational plaque psoriasis treatments show promise in late-stage trials	Mar. 11	AQ
Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million	Mar. 11	RE
What is Ireland's exposure to the US economy and Trump's plans?	Mar. 11	RE
J&J: to present its advances in digital orthopedics	Mar. 11	CF
Sector Update: Health Care Stocks Decline Late Afternoon	Mar. 10	MT
Top Midday Gainers	Mar. 10	MT
India's Syngene International acquires first US biologics facility for $36.5 mln	Mar. 10	RE
Genmab Says Johnson & Johnson Will Not Exercise Option For Hexabody-Cd38 License	Mar. 10	RE
Johnson & Johnson - Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis	Mar. 10	AQ
Genmab to Halt Blood Cancer Treatment Development Amid J&J Decision	Mar. 10	MT
Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option	Mar. 10	DJ

2e66a5c440cabc2.juJw4ET2x26cL6ZtnjdkXbrtMQcZ2WzDuP9vq6Oku2w.utBAgwyj9ADYVec9_EUuadDVf2FwgFyq06gczurA4g_G2gWnfYOUD8t5kg

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

J&J to Buy Intra-Cellular for About $14 Billion

January 13, 2025 at 12:32 pm EST